Pertuzumab (Perjeta) — HER2 antibody treatment for selected breast cancers

What pertuzumab is in simple patient language

Perjeta is the brand name. Pertuzumab is the drug name in medical records. An antibody by vein. Not a tablet. Not classic chemotherapy. Not immunotherapy.

It comes up when a breast tumor shows a strong HER2 signal. Without that result, the name Perjeta usually does not help the plan.

The first question is practical. Why now? Before surgery? After surgery? A disease that has spread? With trastuzumab? With chemotherapy? The same drug can have a different job in each story.

The file also has to show the body side of the story. Heart function. Past treatment. Infusion reactions. Diarrhea. Blood counts. Strength at home. A HER2 result is only one piece.

How pertuzumab works

Some breast cancer cells use HER2 as a loud growth message. The cell keeps hearing a signal to grow and divide.

Pertuzumab attaches to part of that HER2 system. In plain words, it tries to make the growth message less useful to the cancer cell.

It is usually not used as a lonely drug. Very often the plan also has trastuzumab and another treatment. One medicine blocks one part of the HER2 story. Another medicine works from a different side.

The doctor reads the result slowly. Tumor size, scans, symptoms, blood tests, heart checks, diarrhea, infusion reactions, and the whole treatment goal all matter together.

Which diseases pertuzumab may be used for

Pertuzumab belongs only in selected breast cancer plans where HER2 is truly part of the disease story.

• breast cancer with a clear HER2 result
• treatment before surgery when the tumor needs to shrink first
• treatment after surgery when the return risk is still a concern
• breast cancer that has spread and needs treatment for the whole body
• a plan where trastuzumab and chemotherapy are being discussed
• a second opinion when Perjeta was offered and the reason is not clear

HER2 alone does not finish the discussion. Stage, surgery plan, old drugs, heart function, side effects, and the patient’s strength can change the route.

When pertuzumab can be especially relevant

Perjeta often enters the talk when HER2 treatment needs more than one angle.

• the tumor is large enough that treatment before surgery is being discussed
• the doctor wants to lower the chance of the disease coming back
• the disease has spread and the first HER2 plan is being built
• trastuzumab is already part of the plan and the question is whether another antibody should sit next to it
• the family wants to understand why chemotherapy is being paired with HER2 antibodies
• heart safety has to be checked before a long plan starts

The useful question is not “is Perjeta strong?” The useful question is what it is meant to do for this patient now.

What needs to be checked before treatment

A short discharge letter is not enough. The doctor needs the tumor facts and the treatment road so far.

• biopsy report and exact tumor type
• HER2 result, and extra confirmation if the first result was unclear
• ER and PR results
• current stage and recent scans
• past surgery, chemotherapy, radiation, trastuzumab, or other HER2 drugs
• heart echo or another heart function check
• blood count, liver values, kidney values, and general chemistry
• diarrhea, nausea, weight loss, swelling, breathlessness, or chest symptoms
• pregnancy question, when it is relevant
• all regular medicines and any past infusion reaction

Sometimes the next step is not another drip right away. It may be a heart review, repeat HER2 reading, recovery after surgery, or a change in the whole order of treatment.

How treatment with pertuzumab goes

Pertuzumab is given through a vein in a clinic. The schedule comes from the oncology team. It is usually part of a wider HER2 plan.

The first infusion is watched closely. The team wants to know about chills, heat, rash, tight chest, breathing trouble, dizziness, or sudden weakness during the drip.

During treatment, the usual checks are practical:

• how the patient feels during and after the infusion
• temperature, rash, chills, or any reaction during the drip
• blood count, especially when chemotherapy is in the same plan
• loose stool, nausea, appetite, and drinking enough fluids
• heart function checks on the planned schedule
• swelling, short breath, fast heartbeat, or new fatigue with walking
• scans or clinic exams that show how the disease is moving

A hard week does not always close the door on treatment. The answer may be support medicine, fluids, a pause, a heart check, or a change in the other drug in the plan.

Possible side effects

Pertuzumab can help in the right HER2 plan, but the body still needs watching. Some problems come from Perjeta. Some come from the medicines given with it.

Possible problems include:

• loose stool, belly cramps, nausea, or poor appetite
• tiredness or low energy after treatment
• rash, itching, dry skin, or nail and mouth soreness
• chills, heat, rash, chest tightness, or breathing trouble during the infusion
• lower white cells or infection signs when chemotherapy is also used
• swelling, short breath, fast heartbeat, or unusual tiredness with activity
• changes in blood tests during the course

The patient does not need to panic over every symptom. Silence is the risky part. A small problem is easier to sort out early.

When the treating team needs to know fast

Call or message the treating team the same day if any of this starts:

• breathing trouble, chest pressure, swelling of the face or throat, or fainting during the drip
• fever, shaking cold, or feeling suddenly unwell after treatment
• loose stool many times in one day, belly pain, dry mouth, or not drinking enough
• new short breath, leg swelling, fast heartbeat, or chest pain
• rash that spreads quickly or becomes painful
• vomiting that does not settle, or a fast drop in strength
• any symptom that feels very different from the usual recovery week

Do not try to prove at home that Perjeta caused it. The team needs to decide that.

Why pertuzumab is not right for everyone

Perjeta is useful only when the HER2 story and the patient story fit. It is not a general breast cancer drug.

• the HER2 result does not support this plan
• the heart function is already too weak for this route
• there was a serious reaction to a similar antibody
• infection, weakness, or recovery after surgery makes the timing unsafe
• the current stage of treatment needs another route first
• side effects from previous treatment make the combination too heavy
• pregnancy or pregnancy risk changes the discussion

Choosing another plan does not mean Perjeta is a bad drug. It may simply be the wrong tool for this tumor, this heart, or this moment.

Can pertuzumab be combined with other treatments

Yes. Most Perjeta plans are combination plans. The point is not to add more names. Each part needs a reason.

• with trastuzumab as the other HER2 antibody
• with chemotherapy when that belongs to the stage of treatment
• before surgery if the goal is to shrink the tumor first
• after surgery if the risk story supports a stronger HER2 plan
• with radiation or hormone treatment as part of the wider breast cancer plan
• with support for diarrhea, nausea, rash, low blood counts, or fatigue

More drugs can bring more control. They can also bring more side effects. The patient should know what each part is doing and what will be watched.

What no quick response can mean

A quick answer is not always visible. The patient may already be getting infusions while the scans still need time.

Sometimes the tumor shrinks. Sometimes the useful result is steadier disease. After surgery, the job may be even less visible: lowering the chance of a return later.

The doctor does not read one day alone. Scans, breast exam, symptoms, heart function, blood tests, side effects, and the original goal of treatment all need to be put together.

Oncology consultation in Israel about pertuzumab

At Tel Aviv Medical Clinic, a patient with breast cancer can discuss whether pertuzumab has a clear place in the current plan. This can help when Perjeta was offered, but the reason, the timing, or the risks are not clear.

A consultation may help to:

• review the HER2 result and whether the test story is complete
• understand why Perjeta is being discussed now
• look at the plan before surgery or after surgery
• compare the HER2 treatment options that may fit this case
• check heart risk before the plan starts
• prepare questions for the treating oncologist
• discuss which options may be relevant in Israel

We do not prescribe remotely and do not replace the treating physician. We help the patient and family understand the medical logic and prepare for the next step.

Frequently asked questions — answered by Dr. Stefanska

1. Is Perjeta the same as trastuzumab?

No. They are both HER2 antibodies, but they are not the same drug. They can be used together because they touch the HER2 story from different sides.

I do not explain it as one being “better” in a simple way. I look at the whole plan. Why add Perjeta? Is there chemotherapy next to it? Is this before surgery, after surgery, or for disease that has spread? That is the real question.

2. Why does the HER2 report matter so much?

Because Perjeta needs a real HER2 target. The breast cancer name alone is not enough.

I want to see the actual biopsy report. How strong was HER2? Was there an extra test? Was the sample old? Did the disease change after earlier treatment? A small line in a discharge letter is not enough for this decision.

3. Why is the heart checked before treatment?

HER2 treatment can put stress on the heart in some patients. Most people do not feel anything at the start, so we check before guessing.

I want the heart result before treatment begins. I also want to know about old heart disease, chest pressure, breathing changes, puffy ankles, or heavy tiredness. If a problem appears later, we need to catch it early.

4. Is Perjeta always given with chemotherapy?

Often, but the exact plan changes by stage. Before surgery, the plan may look different from treatment after surgery or treatment for spread disease.

I always read the whole schedule, not only the Perjeta name. The side effects may come from the antibody, from trastuzumab, from chemotherapy, or from the mix. The patient needs to know the full plan.

5. What should I do if diarrhea starts?

Tell the team early. Do not wait until the patient is weak and dry.

Loose stool may stay mild. It may also become a reason for fluids, medicine, tests, or a pause in part of the plan. I want to know how many times a day, whether there is pain or fever, and whether the patient can drink.

6. Can I ask for a second opinion before starting Perjeta?

Yes. A second opinion is very reasonable when the plan has several drugs and a long goal.

Send the biopsy, HER2 result, ER and PR, scans, heart check, old treatment list, and the plan offered by the treating doctor. Then we can discuss whether Perjeta has a clear job in this case.

7. What should be sent for a consultation about Perjeta?

Send the papers that tell the story: biopsy, HER2 testing, hormone receptors, current scans, surgery notes if there were any, heart echo, blood tests, and old treatment dates.

Add one simple page. When was the diagnosis? What was given? What helped? What failed? Why is Perjeta being discussed now? That page often helps more than a pile of mixed files.

Important information

This page gives general medical information only. It is not a treatment recommendation. Pertuzumab is discussed only after review of the diagnosis, HER2 result, stage, scans, heart function, past treatment, side effect risks, and general condition.

Do not start, stop, or change treatment without speaking with the treating physician.

Contacts

For a consultation about pertuzumab:

📞 +972-73-374-6844

📧 [email protected]

💬 WhatsApp: +972-52-337-3108